IL165953A0 - Biologically active compounds - Google Patents
Biologically active compoundsInfo
- Publication number
- IL165953A0 IL165953A0 IL16595304A IL16595304A IL165953A0 IL 165953 A0 IL165953 A0 IL 165953A0 IL 16595304 A IL16595304 A IL 16595304A IL 16595304 A IL16595304 A IL 16595304A IL 165953 A0 IL165953 A0 IL 165953A0
- Authority
- IL
- Israel
- Prior art keywords
- sup
- sub
- compounds
- diseases
- nhs
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000004171 Cathepsin K Human genes 0.000 abstract 1
- 108090000625 Cathepsin K Proteins 0.000 abstract 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000008355 cartilage degradation Effects 0.000 abstract 1
- 239000002852 cysteine proteinase inhibitor Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000024693 gingival disease Diseases 0.000 abstract 1
- 208000007565 gingivitis Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0216525A GB0216525D0 (en) | 2002-07-16 | 2002-07-16 | Biologically active compounds |
| GB0217239A GB0217239D0 (en) | 2002-07-25 | 2002-07-25 | Biologically active compounds |
| US41852402P | 2002-10-15 | 2002-10-15 | |
| PCT/GB2003/002957 WO2004007501A1 (en) | 2002-07-16 | 2003-07-15 | Biologically active compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL165953A0 true IL165953A0 (en) | 2006-01-15 |
Family
ID=30118828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16595304A IL165953A0 (en) | 2002-07-16 | 2004-12-23 | Biologically active compounds |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20060100431A1 (zh) |
| EP (1) | EP1546150B1 (zh) |
| JP (1) | JP2006504651A (zh) |
| CN (1) | CN100354276C (zh) |
| AT (1) | ATE424401T1 (zh) |
| AU (1) | AU2003255711B2 (zh) |
| BR (1) | BR0312662A (zh) |
| CA (1) | CA2499465A1 (zh) |
| DE (1) | DE60326473D1 (zh) |
| HK (1) | HK1084115A1 (zh) |
| IL (1) | IL165953A0 (zh) |
| NZ (1) | NZ537853A (zh) |
| WO (1) | WO2004007501A1 (zh) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006109085A1 (en) | 2005-04-13 | 2006-10-19 | Astex Therapeutics Limited | Hydroxybenzamide derivatives and their use as inhibitors of hsp90 |
| GB0513841D0 (en) * | 2005-07-07 | 2005-08-10 | Medivir Ab | Cysteine protease inhibitors |
| RU2008109025A (ru) * | 2005-08-10 | 2009-09-20 | Амура Терапьютикс Лимитед (Gb) | Получение производных диазапенталена эпоксидированием дигидропирролов |
| GB0517279D0 (en) * | 2005-08-23 | 2005-10-05 | Amura Therapeutics Ltd | Biologically active compounds |
| WO2007082808A2 (en) | 2006-01-18 | 2007-07-26 | F. Hoffmann-La Roche Ag | Thiazoles as 11 beta-hsd1 inhibitors |
| US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| US8912315B2 (en) | 2006-03-08 | 2014-12-16 | Japan Science And Technology Agency | Purkinje cell-tropic viral vector |
| RU2435569C2 (ru) | 2006-03-16 | 2011-12-10 | Трис Фарма, Инк. | Композиции с модифицированным высвобождением, содержащие комплексы лекарственное вещество - ионообменная смола |
| GB0614042D0 (en) | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| WO2008044045A1 (en) * | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5528806B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| WO2008044054A2 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Hydroxy-substituted benzoic acid amide compounds for use in therapy |
| US8779132B2 (en) | 2006-10-12 | 2014-07-15 | Astex Therapeutics Limited | Pharmaceutical compounds |
| JP5721949B2 (ja) | 2006-10-12 | 2015-05-20 | アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 複合薬剤 |
| EP2719700A1 (en) | 2008-01-09 | 2014-04-16 | Amura Therapeutics Limited | Tetrahydrofuro(3,2-b)pyrrol-3-one derivatives as inhibitors of cysteine proteinases |
| GB0806527D0 (en) | 2008-04-11 | 2008-05-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| WO2012099785A2 (en) | 2011-01-20 | 2012-07-26 | The Regents Of The University Of Colorado, A Body Corporate | Modulators of tlr3/dsrna complex and uses thereof |
| WO2015130806A1 (en) | 2014-02-25 | 2015-09-03 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of complement mediated disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| US10000516B2 (en) | 2015-08-26 | 2018-06-19 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
| US10385097B2 (en) | 2015-08-26 | 2019-08-20 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| AR105808A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
| WO2017035361A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
| WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
| ES2908479T3 (es) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| ES2933513T3 (es) | 2017-03-01 | 2023-02-09 | Achillion Pharmaceuticals Inc | Compuestos macrocíclicos para el tratamiento de trastornos médicos |
| JP7133561B2 (ja) | 2017-03-01 | 2022-09-08 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 医学的障害の治療のためのアリール、ヘテロアリール及び複素環式医薬化合物 |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| EP3846803A4 (en) | 2018-09-06 | 2022-08-10 | Achillion Pharmaceuticals, Inc. | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
| AU2019336238A1 (en) | 2018-09-06 | 2021-04-08 | Achillion Pharmaceuticals, Inc. | Morphic forms of Complement factor D inhibitors |
| JP2022502500A (ja) | 2018-09-25 | 2022-01-11 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体因子ｄ阻害剤の形態 |
| TW202334135A (zh) * | 2021-11-02 | 2023-09-01 | 美商雅力雅製藥公司 | 化合物、組合物及方法 |
| WO2023081662A1 (en) * | 2021-11-02 | 2023-05-11 | Aria Pharmaceuticals, Inc. | Bicyclic derivatives as ccr2 modulators |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR013079A1 (es) * | 1997-05-06 | 2000-12-13 | Smithkline Beecham Corp | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios |
| GB9911417D0 (en) * | 1999-05-18 | 1999-07-14 | Peptide Therapeutics Ltd | Furanone derivatives as inhibitors of cathepsin s |
| ATE356130T1 (de) * | 2001-01-17 | 2007-03-15 | Amura Therapeutics Ltd | Inhibitoren von cruzipain und anderen cysteinproteasen |
-
2003
- 2003-07-15 NZ NZ537853A patent/NZ537853A/xx unknown
- 2003-07-15 AU AU2003255711A patent/AU2003255711B2/en not_active Expired - Fee Related
- 2003-07-15 WO PCT/GB2003/002957 patent/WO2004007501A1/en active Application Filing
- 2003-07-15 EP EP03763972A patent/EP1546150B1/en not_active Expired - Lifetime
- 2003-07-15 AT AT03763972T patent/ATE424401T1/de not_active IP Right Cessation
- 2003-07-15 BR BR0312662-5A patent/BR0312662A/pt not_active IP Right Cessation
- 2003-07-15 CN CNB038219255A patent/CN100354276C/zh not_active Expired - Fee Related
- 2003-07-15 US US10/521,354 patent/US20060100431A1/en not_active Abandoned
- 2003-07-15 DE DE60326473T patent/DE60326473D1/de not_active Expired - Lifetime
- 2003-07-15 CA CA002499465A patent/CA2499465A1/en not_active Abandoned
- 2003-07-15 JP JP2004520827A patent/JP2006504651A/ja active Pending
-
2004
- 2004-12-23 IL IL16595304A patent/IL165953A0/xx unknown
-
2006
- 2006-04-12 HK HK06104442A patent/HK1084115A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006504651A (ja) | 2006-02-09 |
| CN100354276C (zh) | 2007-12-12 |
| AU2003255711B2 (en) | 2008-11-13 |
| EP1546150B1 (en) | 2009-03-04 |
| CN1681817A (zh) | 2005-10-12 |
| EP1546150A1 (en) | 2005-06-29 |
| CA2499465A1 (en) | 2004-01-22 |
| AU2003255711A1 (en) | 2004-02-02 |
| DE60326473D1 (en) | 2009-04-16 |
| WO2004007501A1 (en) | 2004-01-22 |
| US20060100431A1 (en) | 2006-05-11 |
| NZ537853A (en) | 2007-02-23 |
| HK1084115A1 (en) | 2006-07-21 |
| BR0312662A (pt) | 2005-05-03 |
| ATE424401T1 (de) | 2009-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1084115A1 (en) | Biologically active compounds | |
| UY26625A1 (es) | Inhibidores de proteasas | |
| HUP0401431A2 (hu) | Cisztein proteáz inhibitorok 2-ciano-4-amino-pirimidin szerkezettel és katepszin K inhibitor hatással, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| IL143142A0 (en) | Protease inhibitors | |
| NO20051225L (no) | 1,2,4- oksadiazoler som modulatorer av metabotropisk glutamat-reseptor-5 | |
| SE0200920D0 (sv) | Novel compounds | |
| MY137099A (en) | Azaindoles | |
| SI1767535T1 (sl) | Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh | |
| IL165262A (en) | Kinase inhibitors and pharmaceutical compositions containing them | |
| IS2833B (is) | 1,5 Bensóþíósepín og notkun þeirra gegn fitublæði | |
| NO20052496L (no) | Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter. | |
| AP9801222A0 (en) | Proatease inhibitors. | |
| TW200500341A (en) | Novel compounds | |
| ATE311380T1 (de) | Durch säuregruppen disubstitierte heteroaryl- derivate und ihre verwendung als matrix metalloproteinas inhibitoren | |
| NO20052520D0 (no) | Nye sulfamider | |
| MXPA03006224A (es) | Inhibidores de cruzipaina y otras proteasas de cisteina. | |
| ATE400270T1 (de) | Pharmazeutische zusammensetzungen mit sertaconazol für vaginale verwendung | |
| AR022423A1 (es) | Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento | |
| NO995268L (no) | Proteaseinhibitorer | |
| NO965459L (no) | 2-ureido-benzamidderivater | |
| SE0101038D0 (sv) | Novel compounds | |
| MXPA02012442A (es) | Inhibidores de proteasa. | |
| WO1999059526A3 (en) | Protease inhibitors | |
| DK1525188T3 (da) | Hidtil ukendte derivater af 4,4-dithiobis-(3-aminobutan-1-sulfonater) og sammensætninger, der indeholder dem | |
| ZA944727B (en) | Phosphonic acid compounds processes for preparing them and pharmaceutical compositions containing them |